This substantial investment will enable the Institute to continue its world-leading research into the fundamental causes of inflammatory and musculoskeletal diseases, while accelerating the development of new and improved therapies.
The funding will underpin KIR's distinctive discovery-to-translation pipeline, an approach that integrates fundamental scientific discovery with clinical application. This unique model enables researchers to translate insights from basic biology into innovative treatments for conditions including arthritis, fibrosis and inflammatory bowel disease.
Over the next five years, the funding will support KIR's core research programmes, early-career researchers and students, as well as its research culture initiatives, industry partnerships, and academic events.
The Kennedy Trust for Rheumatology Research is a charitable organisation dedicated to advancing basic and translational research into musculoskeletal and related inflammatory diseases. Since 2011, it has provided more than £100 million in continuous core funding to the KIR, enabling sustained scientific progress and long-term innovation.